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Abstract
Background:  Hydrolethalus syndrome (HLS) is a severe fetal malformation syndrome
characterized by multiple developmental anomalies, including central nervous system (CNS)
malformation such as hydrocephaly and absent midline structures of the brain, micrognathia,
defective lobation of the lungs and polydactyly. Microscopically, immature cerebral cortex,
abnormalities in radial glial cells and hypothalamic hamartoma are among key findings in the CNS
of HLS fetuses. HLS is caused by a substitution of aspartic acid by glycine in the HYLS1 protein,
whose function was previously unknown.
Results: To provide insight into the disease mechanism(s) of this lethal disorder we have studied
different aspects of HLS and HYLS1. A genome-wide gene expression analysis indicated several
upregulated genes in cell cycle regulatory cascades and in specific signal transduction pathways
while many downregulated genes were associated with lipid metabolism. These changes were
supported by findings in functional cell biology studies, which revealed an increased cell cycle rate
and a decreased amount of apoptosis in HLS neuronal progenitor cells. Also, changes in lipid
metabolism gene expression were reflected by a significant increase in the cholesterol levels of HLS
liver tissues. In addition, based on our functional studies of HYLS1, we propose that HYLS1 is a
transcriptional regulator that shuffles between the cytoplasm and the nucleus, and that when
HYLS1 is mutated its function is significantly altered.
Conclusion: In this study, we have shown that the HYLS1 mutation has significant consequences
in the cellular and tissue levels in HLS fetuses. Based on these results, it can be suggested that
HYLS1 is part of the cellular transcriptional regulatory machinery and that the genetic defect has a
widespread effect during embryonic and fetal development. These findings add a significant amount
of new information to the pathogenesis of HLS and strongly suggest an essential role for HYLS1 in
normal fetal development.
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Background
Hydrolethalus syndrome (HLS, MIM 236680) is an auto-
somally recessively inherited developmental malforma-
tion syndrome leading to stillbirth or death shortly after
birth. HLS is characterized by a severe central nervous sys-
tem (CNS) malformation with hydrocephaly and absent
midline structures of the brain. The main neuropatholog-
ical findings include a unique open-book appearance of
the brain midline, the 'key-hole' defect in the base of the
scull, a massive accumulation of cerebrospinal fluid, a
dysplastic cortex, agenesis of the hippocampi, hypoplastic
cerebellum and brain stem as well as hypothalamic
hamartoma. Microscopically, disrupted and abnormal
radial glial formation can be seen, as well as a severely dis-
organized cortex with abundant primitive neuroepithelial
rosettes [1]. Other clinical features include micrognathia,
polydactyly of hands and feet, and defective lobation of
the lungs. In addition, the amount of amniotic fluid is
increased, with case reports of up to eight liters at birth
[2,3]. Nowadays, HLS can be effectively detected by ultra-
sound scan, usually in the end of the first trimester of the
pregnancy [4]. HLS is enriched in the Finnish population
with an incidence of at least 1:20,000 [3].
Our earlier studies have revealed a missense mutation in
a novel gene HYLS1 as a causative mutation for HLS [5].
This mutation is an A to G transition leading to a substi-
tution of aspartic acid 211 to glycine (D211G) in the 299
amino acid polypeptide. HYLS1 consists of six exons with
five known splice variants, but only the last exon encodes
for the protein. HYLS1 was seen to have a wide expression
pattern when human fetal cDNAs were studied and the
same was observed in mouse embryonic in situ studies.
When the cellular localization of the HYLS1 protein was
studied in an overexpression cell model we detected the
partially different localization of wild-type (wt) and
mutant forms of the protein. While the wt form localizes
mainly into the cytoplasm, the mutated form partly accu-
mulates in the nucleus forming dot-like structures [5]. The
function of the HYLS1 protein is not known and it lacks
any known functional domains except a low-complexity
region. In addition, the protein is not homologous with
any known protein family. However, the polypeptide has
orthologs among other species with a conserved polypep-
tide domain where the mutation site is located [5].
In this study, we have had an exceptional opportunity to
investigate several cell and tissue samples from HLS cases
and healthy control fetuses with different methods in
order to understand the disease mechanism(s) of this
grievous disorder. In addition, we have obtained impor-
tant novel information about the function of the normal
and mutant HYLS1 protein which has a critical role during
fetal development.
Results
Disease pathogenesis of HLS
Microarray analysis
Owing the dramatic phenotype of HLS fetuses and the
lack of exact information on HYLS1 function, we per-
formed genome-wide gene expression analysis of fetal
skin fibroblast cell lines (HLS N = 3, control N = 4) to
obtain novel data on cellular pathways influencing the
HLS pathogenesis. The quality control of the samples
showed that the control and HLS samples were distinctly
assigned to their own clusters. At the end, we obtained a
total of 802 transcripts to evaluate by analysis of variance
(ANOVA; t-test) statistical testing and as a result, we chose
a statistically significant subgroup of these to be analyzed
further.
Several pathways were significantly differentially
expressed between control and HLS cells (see Figure 1 and
Additional file 1). Difference in the amount of expression
varied from -8.02 to +13.79 in the whole data set. After
examination of the transcript lists (Webgestalt program),
many of the upregulated genes were associated with clas-
sification cell cycle regulation, signal transduction and the
downregulated genes to the general categories of lipid
metabolism and axon guidance (Figure 1). The most
upregulated genes inside the classification groups
included  DUSP6  (dual specificity phosphatase 6, fold-
change 7.06), PDGFA  (platelet-derived growth factor
alpha polypeptide, 3.76), FGF5 (fibroblast growth factor
5, 2.81), CFLAR (CASP8- and FADD-like apoptosis regu-
lator, 2.63), MAP3K5 (mitogen-activated protein kinase
kinase kinase 5, 2.92) and CCND1 (cyclin D1, 2.91). The
downregulated genes related to lipid metabolism
included  LARGE  (like-glycosyltransferase, fold-change -
3.54), SCD (stearoyl-CoA desaturase, -3.50) and ACAT2
(acetyl-Coenzyme A acetyltransferase 2, -3.02). Also LDLR
(low-density lipoprotein receptor, -2.83), DHCR7 (7-
dehydrocholesterol reductase, -2.53) and HMGCS1  (3-
hydroxy-3-methylglutaryl-Coenzyme A synthase 1, -2.20)
were downregulated in the cells derived from the HLS
cases. Downregulated genes related to axon guidance
included SPON2 (spondin 2, -7.15) and NPR2 (neuropi-
lin 2, -3.19).
Proliferation assay and analysis of apoptosis rate
Since we observed upregulation of genes involved in cell
cycle events in the gene expression analysis, we wanted to
further study the cell cycle rate of the HLS cells compared
with control cells. The proliferative activity of HLS and
control neuronal progenitor cells was detected by measur-
ing the incorporation of BrdU (bromodeoxyuridine) and
the proliferating cells were identified by immunocyto-
chemistry. The result of the BrdU assay showed signifi-
cantly elevated proliferation rate of the neuronalPathoGenetics 2009, 2:2 http://www.pathogeneticsjournal.com/content/2/1/2
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Regulated pathways in hydrolethalus syndrome fibroblasts Figure 1
Regulated pathways in hydrolethalus syndrome fibroblasts. Most of the upregulated pathways (A) are involved in cell 
cycle regulation and signal transduction events while the downregulated pathways (B) are mostly involved in lipid metabolism. 
Significantly regulated pathways are marked with a gray background.
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progenitor cells obtained from the HLS fetus compared
with the control cells. The amount of the proliferation was
7.9% in mutant cells, but only 1.7% in control cells, Stu-
dent's t-test showing a statistically significant result with a
p-value of p < 0.001 (Figure 2).
Apoptosis was measured by Annexin staining. A total of
30,000 events per sample were analyzed from which
around 5,000 were actual cells. This population of real
cells was analyzed in accordance with fluorescein isothio-
cyanate (FITC) and propidium iodide (PI) fluorescence.
In control cells the amount of apoptosis was on average
25.6% while in HLS cell samples apoptosis was only 8.7%
(Figure 3). These results show that apoptosis rate in HLS
patient neuronal progenitor cells was highly decreased (p
< 0.05 by Student's t-test). The difference in necrotic cells
between control and patient cell samples was not signifi-
cant (data not shown).
Cholesterol level measurement
Since downregulation of genes involved in lipid metabo-
lism, especially related to the cholesterol pathway, was
observed in the gene expression analysis, we wanted to
analyze whether the levels of lipids differed between the
HLS and control samples. We had an opportunity to use
liver samples collected at the autopsies from two controls
and from three HLS fetuses. After the lipids were extracted
from the cells, concentrations of cholesterol, phospholip-
ids and triglycerides were determined. As a result, the aver-
age hepatic cholesterol level of HLS fetuses (3488 μg/g)
was elevated 25.3% (p < 0.01) when compared with con-
trol samples (2607 μg/g) (Figure 4). Phospholipid as well
as triglyceride levels did not differ in liver samples
between the two groups (p > 0.05) (data not shown). This
result suggests a disturbance in hepatic sterol balance in
affected cells and supports the microarray findings of dif-
ferential expression in lipid pathway between the controls
and the HLS cases.
Functional studies of HYLS1
Nuclear export study
Leptomycin B (LMB) specifically inhibits CRM-1-medi-
ated nuclear export, a process that has recently been
shown to be important for the function of several proteins
[6]. Although HYLS1 lacks the putative export sequences
in silico, the dual subcellular localization of HYLS1 in the
cytoplasm and nucleus [5] suggests that it might, in addi-
tion to most probably being transported into the nucleus,
also be actively exported from it. To test this hypothesis,
Average percentage of bromodeoxyuridine-positive, prolifer- ative control and hydrolethalus syndrome neuronal progeni- tor cells Figure 2
Average percentage of bromodeoxyuridine-positive, 
proliferative control and hydrolethalus syndrome 
neuronal progenitor cells. The amount of the prolifera-
tion is 1.7% in control cells compared with 7.9% in hydrole-
thalus syndrome (HLS) cells. Results are represented as the 
mean from three independent experiments. The p-value 
between groups is p < 0.001.
Determination of apoptotic fractions in control and patient  cell populations by Annexin V stainings Figure 3
Determination of apoptotic fractions in control and 
patient cell populations by Annexin V stainings. In 
control cells the amount of apoptosis was 25.6% while in the 
hydrolethalus syndrome (HLS) cell samples apoptosis was 
highly reduced, being 8.7%. Results are represented as the 
mean from nine (control) and seven (HLS) independent 
experiments. The p-value is p < 0.05 between samples.
Cholesterol levels of control and hydrolethalus syndrome  liver samples Figure 4
Cholesterol levels of control and hydrolethalus syn-
drome liver samples. Cholesterol level of liver (in μg cho-
lesterol/g tissue) in healthy controls is on average 2607 μg/g 
and in hydrolethalus syndrome (HLS) fetuses on average 
3488 μg/g, with the p-value being p < 0.01 between groups.PathoGenetics 2009, 2:2 http://www.pathogeneticsjournal.com/content/2/1/2
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HEK-293 cells were transfected with a construct express-
ing either wt or mutant HYLS1 and subjected to LMB. The
proportion of cells exhibiting either a nuclear, cytoplas-
mic or combined nuclear and cytoplasmic staining pat-
tern was measured. As a result we observed that the
treatment of cells with LMB at 15 ng/ml for 6 hours led to
exclusively nuclear localization of both wt and mutated
HYLS1. After the treatment, both wt and mutant HYLS1
were showing nuclear localization that significantly dif-
fers from the untreated state (both wt and mutant treated
state versus corresponding untreated state p < 0.001 by
Student's t-test). In contrast, without LMB treatment most
of the wt cells had cytoplasmic localization, but mutated
cells localized both in nucleus and cytoplasm (Student's t-
test between untreated wt and mutant p < 0.001) (Figure
5). Variations in the LMB concentration or treatment time
had little effect on the outcome (data not shown). These
results indicate that HYLS1 is shuttled between the
nucleus and cytoplasm.
Transactivation assay
As we have hypothesized previously, HYLS1 might have a
role as a transcriptional activator. To study this hypothesis
we performed a transactivation assay to test whether the
protein possesses transactivation capacity. For this, wt and
mutant HYLS1 in fusion with the Gal4-DBD as well as the
reporter vector pG5LUC were transiently expressed in the
SH-SY5Y neuroblastoma cells. The wt protein was shown
to activate the transcription 9.4-fold compared with a
blank vector, whereas the mutant HYLS1 was capable to
increase the transactivation only 3.4-fold (Figure 6). The
difference between vector and wt is statistically significant
(p < 0.01 with Student's t-test) as well as between vector
and mutant (p < 0.05). Also the difference between the wt
and mutant form of HYLS1 is significant with p < 0.01.
Thus, we conclude that HYLS1 has transactivation capac-
ity and this capacity is significantly decreased in cells con-
taining the mutant form of the protein.
Discussion
HLS is a severe fetal malformation syndrome with a wide
spectrum of phenotypic features and with the pathogenic
mutation situated in a gene with no previously known
function. Therefore, we used a combination of several dif-
ferent research methods to unravel the disease pathogen-
esis behind this lethal syndrome as well as to shed light on
the role of the HYLS1 protein during fetal development.
As described earlier, the structural pattern of the brain is
severely disturbed in HLS fetuses both at the macroscopic
and the microscopic level [1]. Frequent findings include
the absence of the midline structures, a severely disorgan-
ized cortex, disrupted and abnormal formation of radial
glial cells, as well as formation of primitive neuroepithe-
lial rosettes. In current cellular studies, HLS neuronal pro-
genitor cells showed a significantly increased proliferation
rate while the amount of apoptosis was decreased. These
findings are highly interesting because apoptosis is an
essential and precisely controlled phenomenon of con-
trolled cell death both in fetal development and in adult-
hood. When creating animal models with suppressed
apoptosis rate, in many cases genetic reduction or elimi-
nation of cell death led to gross anatomical malforma-
tions or embryonic mortality, in some cases probably as a
Leptomycin B treatment of cells transfected with a construct  expressing either wild-type or mutant HYLS1 Figure 5
Leptomycin B treatment of cells transfected with a 
construct expressing either wild-type or mutant 
HYLS1. Average percentages of cells showing either cyto-
plasmic (white, cells showing cytoplasmic staining only) or 
nuclear (gray, cells showing only nuclear or nuclear and cyto-
plasmic staining) localization are given. After leptomycin B 
treatment (LM+), both wild-type (wt) and mutant (mut) 
HYLS1 are showing nuclear localization that significantly dif-
fers from the untreated state (LM-) (both wt and mutant p < 
0.001). The proportion of nuclear localization in untreated 
mutant cells versus wt cells is also significant (p < 0.001).
Transcriptional activity of HYLS1 Figure 6
Transcriptional activity of HYLS1. SH-SY5Y cells were 
transfected with the reporter vector pG5LUC and pM1 vec-
tor alone (negative control) or with pG5LUC and wild-type 
or mutant HYLS1-expressing constructs. The values repre-
sent the means from three independent experiments. Here p 
< 0.01 between vector and wt HYLS1, p < 0.05 between vec-
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result of continued proliferation of undead cells [7]. This
result nicely supports the reduced amount of apoptosis in
HLS cells and further, the dramatic phenotype of the CNS
and other malformations seen in HLS. Still, the relation-
ship between the reduced rate of apoptosis and the ele-
vated proliferation rate needs additional studies in order
to explain the interaction of these findings and to under-
stand the mechanism causing the severe malformations in
the brain. It would be beneficial to clarify whether one of
these phenomena is the primary and the other the second-
ary symptom occurring during the abnormal brain devel-
opment in HLS.
Among other interesting results in microarray analysis,
neuropilin 2 was found to be downregulated by over
three-fold in HLS cells. Neuropilins function as receptors
for some of the semaphorins, semaphorins in turn acting
as chemorepulsive signal in interneuron migration during
development of the brain cortex. Marin et al used a mouse
model to demonstrate that interneurons expressing
neuropilins avoid entering the striatum because of this
repulsive signal and are thus directed to the cortex [8].
Loss of neuropilin function, in turn, increases the number
of interneurons that migrate into the striatum. When the
expression level of neuropilins is decreased, the correct
migration pattern of interneurons could also be compro-
mised in the brain of the HLS cases. Thus, the expression
array result corresponds well with the findings of dis-
rupted brain architecture in our previous studies [1].
Although highly speculative at the moment, the observed
upregulation of CCND1, in turn, might in its part explain
the hamartoma finding in HLS fetuses since abnormal
expression levels of CCND1 have been linked with devel-
opment of cancer [9]. Also, in a recent report, intestinal
cell kinase (ICK) was found to be mutated in a syndrome
sharing some overlapping symptoms with HLS and ICK
was suggested to be involved in cell-cycle regulation and
apoptosis during mammalian development [10]. This is
of interest as kinases are crucial in several cellular func-
tions including signal transduction and since several
genes related to signal transduction and further, some
genes associated with the protein kinase cascade, were
upregulated in HLS neuronal progenitor cells.
When comparing HLS with other fetal malformation syn-
dromes, Pallister-Hall syndrome (PHS, MIM 146510)
[11,12] that is caused by mutations in the GLI3 gene [13-
15], probably has the most resemblance to HLS. The
shared features between HLS and PHS are polydactyly,
micrognathia, occasional cleft/lip palate, abnormal loba-
tion of lungs, heart defects and hypothalamic hamartoma.
GLI3 is a transcription factor of the Sonic hedgehog
(SHH) pathway and Gli3 deficient mice have been shown
to have a disorganized radial glia structure in the brain
cortex [16], the condition also seen in the brain of HLS
cases [1]. Another syndrome resembling HLS is Smith-
Lemli-Opitz syndrome (SLOS, MIM 270400) [17,18].
SLOS has a wide spectrum of phenotypic features ranging
from a mild disorder with learning and behavioral prob-
lems to a lethal malformation syndrome. Prominent fea-
tures of the syndrome include growth retardation,
microcephaly, holoprosencephaly, ptosis, micrognathia,
cleft palate and postaxial polydactyly. SLOS is caused by
the mutations in the DHCR7 gene [19,20]. These muta-
tions lead to increased levels of 7-dehydrocholesterol and
decreased cholesterol levels in patient serum [21] while
interestingly in our gene expression arrays, DHCR7 was
downregulated by almost three-fold when compared with
the wt cells. Also, increased cholesterol levels were
observed in HLS liver samples. In addition to DHCR7 the
microarray analysis revealed other genes such as
HMGCS1, ACAT2 and LDLR involved in the cholesterol
metabolism that were downregulated. These results sug-
gest that build-up of cholesterol in the liver causes feed-
back downregulation of these genes involved in the
cholesterol metabolism or receptor-mediated endocytosis
of cholesterol in the form of low-density lipoprotein
(LDL) particles from the circulation.
Since PHS and SLOS share several similar features with
HLS there is a possibility that HYLS1 is involved in similar
kinds of molecular pathways as proteins behind these syn-
dromes. Thus, it is tempting to hypothesize that HYLS1
directly or indirectly affects the function of the SHH sign-
aling pathway. Since HYLS1 has significant transactiva-
tional capacity it could function as a transcriptional
regulator in some stage of the SHH pathway as GLI3 does.
On the other hand, as several genes related to lipid metab-
olism show downregulation in HLS cells and as SHH pro-
tein is dependent on cholesterol to function properly,
HYLS1 could function indirectly in SHH signaling via
cholesterol metabolism pathway instead of being directly
part of the SHH pathway.
As a result of the essential new studies in cellular level, we
found out that the transcriptional activity of HYLS1 is sig-
nificantly decreased when mutated. In addition, we know
that the subcellular localization differs between wt and
mutant forms of HYLS1. Based on these results, it can be
hypothesized that HYLS1 is a part of the transcription reg-
ulatory machinery and that different results between the
wt and the mutant protein are a result of the conforma-
tional change in protein structure caused by the amino
acid substitution. It still remains to be solved whether the
amino acid change results in difficulty in the exportation
of HYLS1 from the nucleus to cytoplasm, which disturbs
the function of the protein. Another possibility is that the
mutated HYLS1 is unable to reach the activity level
required for normal function and this leads to disturbed
downstream pathway regulation or that the possible con-PathoGenetics 2009, 2:2 http://www.pathogeneticsjournal.com/content/2/1/2
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formational change in the mutated form of HYLS1 some-
how disturbs normal developmental pathway(s) when it
is mutated and, thus, leads to the extensive amount of
severe symptoms.
Conclusion
In this study, we have demonstrated through several anal-
yses the significant consequences that the HYLS1mutation
causes in the cellular and tissue levels. As a conclusion, we
suggest that HYLS1 is a transcriptional regulator function-
ing in central pathway(s) related to fetal developmental
processes. The results presented here add a significant
amount of new information of the HLS pathogenesis and
although the subject of the study is a rare malformation
syndrome, these findings strongly suggest an essential role
for HYLS1 in normal fetal development.
Methods
Subjects and samples
This study has been approved by the ethical committees of
Joint Authority for the Hospital District of Helsinki and
Uusimaa, Finland. The controls were age-matched healthy
fetuses aborted for social reasons. The parents' consent
was obtained for the collection and study of the autopsy
samples.
Cell culture
Embryonic skin fibroblast cells obtained from the control
and HLS fetuses as well as commercial human embryonic
kidney cell line (HEK-293) were cultured as monolayers
in Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% bovine calf serum, 100 units/ml peni-
cillin and 100 units/ml streptomycin. SH-SY5Y human
neuroblastoma cells were cultured as monolayers in 1:1
mixture of Ham's F12 and DMEM supplemented with
10% bovine calf serum, 100 units/ml penicillin, 100
units/ml streptomycin and 0.1% nonessential amino
acids. In order to obtain neuronal progenitor cells, cortical
biopsies were collected at autopsy. The autopsy was per-
formed for each fetus within 5 hours of delivery. Neuronal
progenitor cell lines were initiated by homogenizing brain
tissue with pipetting and filtering prior to culture. The
cells were cultured as neurospheres in serum free progen-
itor cell medium, consisting of DMEM supplemented
with 20 ng/ml of basic fibroblast growth factor (FGF,
Sigma-Aldrich, St. Louis, MO, USA), 40 ng/ml of epider-
mal growth factor (EGF, Sigma-Aldrich) and 10 ng/ml of
leukemia inhibitory factor (LIF, Chemicon International,
Temecula, CA, USA). All cells were maintained at +37°C
in a 5% CO2 atmosphere.
Microarray analysis
Microarray analysis was performed according to the
Affymetrix standard protocol (Affymetrix, Santa Clara,
California, USA). In brief, total RNA was extracted with
Trizol reagent (Invitrogen, Carlsbad, California, USA) and
RNeasy Mini kit (Qiagen, Venlo, the Netherlands). Quan-
tity of the RNA was determined with UV-spectrometry and
the quality was controlled with the Agilent Bioanalyzer
2100 (Agilent Technologies, Palo Alto, California, USA).
The cRNA was fragmented and hybridized to Affymetrix
HG-U133 Plus 2.0 chips (Affymetrix) as described in the
protocol. Post-hybridization procedures including wash-
ing, staining and scanning were performed according to
the Affymetrix protocol.
Analysis of gene expression data
Cell intensity files (CEL) and chip files (CHP) were gener-
ated from images of the scanned arrays using Affymetrix
Gene Chip Operating Software (Affymetrix) with the
default settings recommended by the manufacturer. The
CEL files are accessible through the ArrayExpress accession
E-MEXP-1900 [22]. All further data processing was carried
out using the GeneSpring 7.1 data analysis software (Sili-
con Genetics, Redwood City, California, USA). CEL files
were normalized using the GC-RMA algorithm [23] with
default settings, while the cross gene error model imple-
mented in GeneSpring was used to determine cut-offs for
lowest reliable signal intensities. The expression level of
each gene was then equally scaled through median center-
ing. Unreliable data was filtered out using a filtering strat-
egy based on Affymetrix detection calls, which were
extracted from the CHP files and imported into Gene-
Spring. In order to pass the filter genes had to score a mar-
ginal or present call in all arrays, or absent in all arrays
pertaining to one condition while marginal or present in all
arrays of the other condition. Hierarchical clustering,
based on average linkage and Pearson's correlation, and
principal component analysis (PCA) were performed to
identify arrays with outlier behavior, compared with their
biological replicates representing the same condition. A
two-step process was employed to identify differentially
expressed genes. First, genes with less-prominent changes
in gene expression between affected subjects and controls
were excluded by requiring a fold change of at least two.
The remaining genes were tested for statistically signifi-
cant changes in expression using Student's t-test for inde-
pendent samples. We corrected p-values to account for
multiple testing using the method of Benjamini and
Hochberg [24], using a 12% false discovery rate as a cut-
off for significance. Lists of significantly up/downregu-
lated genes were examined for biologically relevant asso-
ciations using the web-based gene set analysis toolkit
WebGestalt [25,26].
Proliferation assay
In vitro study of the neuronal progenitor cell proliferation
was performed using the BrdU labeling method. Neuro-
nal precursor cells (HLS N = 1, control N = 2) maintained
in culture were supplied with 1:1,000 BrdU (AmershamPathoGenetics 2009, 2:2 http://www.pathogeneticsjournal.com/content/2/1/2
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Biosciences UK Limited, Buckinghamshire, England) and
kept in nondifferentiating media for 12–15 hours. After
incubation the cells were attached to coverslips with a cyt-
ospin centrifuge and fixed with 4% PFA for 20 minutes.
The BrdU positive cells were stained using the BrdU anti-
body kit (RPN 202, Amersham Biosciences). The ratio
between the whole cell content and the amount of prolif-
erating cells was counted. The experiment was repeated
three times and all samples were prepared in duplicate.
Samples were grown in several aliquots and pooled
together for the analysis to minimize the effects of passage
and aliquot differences. Stained cells were analyzed with a
Zeiss Axioplan 2 fluorescence microscope.
Analysis of apoptosis rate
The amount of apoptosis was measured by Annexin-V-
Fluos staining kit (Roche, Basel, Switzerland). Undifferen-
tiated neurospheres, each sample (HLS N = 1, control N =
2) containing approximately 1 × 106 cells were harvested,
dissociated into single cells and double stained with FITC-
conjugated annexin (FA) and propidiumiodide (PI) for 15
minutes at room temperature and diluted (1:50 both)
into HEPES buffer according to the manufacturer's proto-
col. Negative controls were treated by the same way but
without one of the appropriate stainings (only FA or PI).
Cells exposed to UV-light, dexamethasone or hydroxyurea
were used as positive controls to ensure functionality of
the assay. Unspecific labeling of FITC was excluded by
treating the cells with IgG-conjugated FITC. Annexin
labels both apoptotic and necrotic cells while living cells
remain unstained. Necrotic cells were excluded by PI
staining, which stains DNA of leaky necrotic cells only.
The amount of labeled cells was measured by flow cytom-
etry (FACSaria, BD Biosciences, San Jose, California,
USA). Measurements were repeated altogether nine times
for control cells and seven times for HLS cells.
Cholesterol and phospolipid level measurement
Cholesterol and phospholipid levels were measured from
fetal liver tissue from two healthy controls and two HLS
fetuses. Total lipids were extracted from whole liver
homogenates using the Folch extraction [27]. Briefly, fro-
zen liver tissue was cut into 5–15 mg pieces and homoge-
nized in a 2:1 methanol-chloroform solvent.
Homogenization was performed with Precellys 24
homogenizer (Bertin technologies, Montigny-le-Breton-
neux, France) according to the manufacturer's protocol
with slight modifications. The homogenized media were
centrifuged briefly to separate out the cell debris. The
supernatant with extracted lipids was transferred to meth-
ylene chloride-purified Kimax tubes and the solvent was
evaporated in a nitrogen atmosphere. The dried lipids
were kept at -20°C until lipid assays. The samples were re-
dissolved in methanol and cholesterol, phospholipids
and triglycerides were analyzed in triplicates according to
the manufacturer's protocol (Roche/Hitachi, Basel, Swit-
zerland for cholesterol and triglycerides, Wako, Neuss,
Germany for phospholipids).
Nuclear export study
In nuclear export studies, HEK-293 cells were transfected
in the following manner: 1 × 106 cells were grown on cov-
erslips in six-well plates and transfected with 1 μg of the
appropriate expression vector, containing either wt or mut
HYLS1 with the Myc sequence immediately before the
start codon. LMB (Tocris Bioscience, Bristol, UK) was
added to cells 24 hour post-transfection initially at 5, 10,
15 or 20 ng/ml, the cells were grown for 3, 6 or 24 hours
and stained as described below. In subsequent experi-
ments, 15 ng/ml LMB was used. Transfections of each
individual vector were performed in duplicate and the
study was repeated three times. For immunofluorescence
studies, cells were fixed with 4% paraformaldehyde (PFA)
in phosphate buffered saline (PBS; pH 7.3) at room tem-
perature (RT) for 10 minutes and blocked and permeabi-
lized with 0.2% saponin/0.5% bovine serum albumin
(BSA) in PBS. Cells were then incubated with primary
antibody (mouse anti-c-myc, Santa Cruz Biotechnology,
Santa Cruz, California, USA) for 1 hour at RT. After wash-
ing, cells were incubated with anti-mouse Texas Red sec-
ondary antibody for 40 minutes at RT. After final washes,
cells were mounted onto microscope slides with Vectash-
ield hard set mounting medium containing 4',6-diamid-
ino-2-phenylindole (DAPI; Vector Laboratories) and the
data was acquired using an Axioplan Z imaging fluores-
cence microscope and AxioVision Rel. 4.6 program. The
proportion of cells showing either cytoplasmic, nuclear or
combined cytoplasmic and nuclear staining was calcu-
lated.
Transactivation assay
SH-SY5Y cells were seeded onto 12-well plates at 1.2 × 105
cells per well. The cells were transfected 24 hours after
seeding with 750 ng of wt or mutant human HYLS1
cloned in fusion with Gal4-DBD. In all transfections, 200
ng of reporter vector pG5-LUC (Promega, Mannheim,
Germany) containing Gal4 binding sites was used. The
pM1 vector was used as a negative control. The transfec-
tions were performed using the Fugene HD transfection
reagent (Roche) according the manufacturer's instruc-
tions. The cells were harvested 48 hours after transfection
and the luciferase activity was determined using the Luci-
ferase Assay System (Promega). The luciferase activities
were normalized according to the total protein concentra-
tion of the lysates which were determined by biuret reac-
tion (Novagen, Madison, Wisconsin, USA). All
transfections were performed in triplicate and repeated
three times.PathoGenetics 2009, 2:2 http://www.pathogeneticsjournal.com/content/2/1/2
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